Fig. 8

The prognostic value of the CLTRP score in breast cancer patients with anti-PD-1/PD-L1 therapy. A The expression of immune checkpoints in the high and low CLTRP subgroups. B TIDE, MDSC infiltration, and dysfunction score in the high and low CLTRP subgroups. C The T-cell cytolytic index in the high and low CLTRP subgroups. D Correlation curves between the CLTRP score and T-cell cytolytic index. E Kaplan‒Meier curves of overall survival according to CLTRP subgroups in the GSE177043 cohort. F Boxplot showing the distribution of the CLTRP score between responders and nonresponders. G Bar graph displaying the numbers of patients with clinical responses to anti-PD-1 immunotherapy in the high and low CLTRP subgroups. H and I CLTRP accurately predicted immunotherapy outcomes in the GSE177043 (H) and EGAD00001006608 (I) cohorts. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, measured by unpaired t test